UNLIMITED TURBO LONG - MODERNA | Market Closed - Euronext Paris 12:30:01 2024-06-20 pm EDT | ||
| 8.85 EUR | +1.43% |
|
| Current month | -6.85% | ||
| 1 month | -4.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 8.85 | +1.43% |
| 24-06-19 | 8.725 | -2.62% |
| 24-06-18 | 8.96 | -4.78% |
| 24-06-17 | 9.41 | -0.32% |
| 24-06-14 | 9.44 | -5.69% |
Real-time Euronext Paris
Last update June 20, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| LL4MB | |
| ISIN | NLBNPNL2KAZ6 |
| Date issued | 2023-11-10 |
| Strike | 50.41 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.06 € |
|---|---|
| Lowest since issue | 3.025 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Certificates
- LL4MB Certificat
